ENVB Fundamental Analysis - ENVERIC BIOSCIENCES INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ENVB. ENVB was compared to 196 industry peers in the Pharmaceuticals industry. While ENVB seems to be doing ok healthwise, there are quite some concerns on its profitability. ENVB is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ENVB had negative earnings in the past year.

ENVB had a negative operating cash flow in the past year.

ENVB had negative earnings in each of the past 5 years.

In the past 5 years ENVB always reported negative operating cash flow.

1.2 Ratios

ENVB's Return On Assets of -280.20% is on the low side compared to the rest of the industry. ENVB is outperformed by 92.86% of its industry peers.

ENVB has a worse Return On Equity (-455.09%) than 77.04% of its industry peers.

		Industry Rank	Sector Rank
ROA	-280.2%
ROE	-455.09%
ROIC	N/A

ROA(3y)-267.33%

ROA(5y)-230.52%

ROE(3y)-532.66%

ROE(5y)-403.62%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ENVB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, ENVB has more shares outstanding

Compared to 5 years ago, ENVB has more shares outstanding

ENVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -51.32, we must say that ENVB is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -51.32, ENVB is not doing good in the industry: 91.33% of the companies in the same industry are doing better.

ENVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-51.32

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 2.43 indicates that ENVB has no problem at all paying its short term obligations.

With a Current ratio value of 2.43, ENVB perfoms like the industry average, outperforming 44.90% of the companies in the same industry.

A Quick Ratio of 2.43 indicates that ENVB has no problem at all paying its short term obligations.

ENVB has a Quick ratio (2.43) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.43
Quick Ratio	2.43

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 80.77% over the past year.

EPS 1Y (TTM)80.77%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%73.91%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ENVB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.43% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y95.88%

EPS Next 2Y38.43%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENVB. In the last year negative earnings were reported.

Also next year ENVB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ENVB's earnings are expected to grow with 38.43% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y38.43%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ENVB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ENVERIC BIOSCIENCES INC

NASDAQ:ENVB (10/7/2025, 8:21:45 PM)

After market: 0.6825 -0.01 (-1.98%)

0.6963

+0 (+0.46%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-11 2025-08-11/bmo

Earnings (Next)11-12 2025-11-12/bmo

Inst Owners10.2%

Inst Owner Change0%

Ins Owners6.84%

Ins Owner Change6.85%

Market Cap2.26M

Analysts82.86

Price Target10.2 (1364.89%)

Short Float %12.51%

Short Ratio0.95

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.04
P/tB	1.04
EV/EBITDA	N/A

EPS(TTM)-21.3

EYN/A

EPS(NY)-1.78

Fwd EYN/A

FCF(TTM)-2.01

FCFYN/A

OCF(TTM)-2.01

OCFYN/A

SpS0

BVpS0.67

TBVpS0.67

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-280.2%
ROE	-455.09%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-267.33%

ROA(5y)-230.52%

ROE(3y)-532.66%

ROE(5y)-403.62%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.43
Quick Ratio	2.43
Altman-Z	-51.32

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)80.77%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%73.91%

EPS Next Y95.88%

EPS Next 2Y38.43%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y2.46%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year31.03%

EBIT Next 3Y2.98%

EBIT Next 5Y33.29%

FCF growth 1Y63.07%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y63.01%

OCF growth 3YN/A

OCF growth 5YN/A

ENVERIC BIOSCIENCES INC (ENVB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens